Maria Borrero

ORCID: 0000-0002-0845-2525
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Economic and Financial Impacts of Cancer
  • Global Cancer Incidence and Screening
  • Global Health Workforce Issues
  • Advanced Breast Cancer Therapies
  • Health disparities and outcomes
  • Nigella sativa pharmacological applications
  • Cannabis and Cannabinoid Research
  • Public Health Policies and Education
  • Childhood Cancer Survivors' Quality of Life
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Medical Education and Admissions
  • Diversity and Career in Medicine
  • Ethics in Clinical Research
  • Colorectal Cancer Screening and Detection
  • Interpreting and Communication in Healthcare
  • Family Support in Illness

University of Minnesota
2023-2024

University of Minnesota System
2023

Abstract Introduction While demographic risk factors of cancer‐related financial hardships have been studied, having minor children or being single rarely assessed in the context healthcare‐related hardships. Methods Using data from 2015 to 2018 National Health Interview Survey, we hardship (material and psychological hardship; behavioral coping due costs: delaying/foregoing care, reducing prescription costs, skipping specialists follow‐up care) among adults aged 18–59 years with cancer ( N...

10.1002/cam4.7088 article EN cc-by Cancer Medicine 2024-03-01

This JAMA Oncology Patient Page discusses classification of breast cancer and ERBB2 status.

10.1001/jamaoncol.2022.6889 article EN JAMA Oncology 2023-02-23

12078 Background: Minnesota currently has a medical cannabis program and recently legalized recreational in 2023. Evidence suggests that may have positive effects on various aspects of cancer patient's quality life. However, little is known about any differences use between rural urban patient populations. We compared use, behaviors, attitudes, access, associations with cancer-related symptom burden versus Minnesotans cancer. Methods: conducted cross-sectional survey 2021 2022. Study...

10.1200/jco.2024.42.16_suppl.12078 article EN Journal of Clinical Oncology 2024-06-01

e24129 Background: Aromatase inhibitors (AIs) are commonly used for postmenopausal women with hormone receptor positive breast cancer. Nearly 2 of 3 on AIs complain AIMSS leading to poor adherence. Preclinical and clinical pilot data suggest topical cannabinoids can reduce inflammation in arthritis. Methods: We conducted a randomized controlled trial assessing the feasibility acceptability two different medical cannabis balms AIMSS. Women stage 1-3 cancer [scoring 4 or higher at least one...

10.1200/jco.2024.42.16_suppl.e24129 article EN Journal of Clinical Oncology 2024-06-01

6547 Background: Oncology clinical research studies (CRS) are essential for developing new therapies and improving patient outcomes, yet the lack of diversity among participants remains an issue. The logistical complexity participating in CRS, funding, limited location study sites, socioeconomic barriers, exclusion non-English speakers (NES) likely contribute to this diversity. In study, we sought evaluate what proportion oncology CRS exclude NES. Methods: We searched ClinicalTrials.gov on...

10.1200/jco.2023.41.16_suppl.6547 article EN Journal of Clinical Oncology 2023-06-01

e18617 Background: The National Breast and Cervical Cancer Early Detection Program's (NBCCEDP) mission is to improve access mammography other health services for underserved women. Research has shown that this national program improved services. However, there limited research describing the total number of individuals eligible utilize these Howard et. al., described women NBCCEDP at state level. Hughes al. have upon with introduction geographic small-area estimation techniques allow us...

10.1200/jco.2023.41.16_suppl.e18617 article EN Journal of Clinical Oncology 2023-06-01
Coming Soon ...